相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。DPP4 in Cardiometabolic Disease Recent Insights From the Laboratory and Clinical Trials of DPP4 Inhibition
Jixin Zhong et al.
CIRCULATION RESEARCH (2015)
Lipoprotein effects of incretin analogs and dipeptidyl peptidase 4 inhibitors
Jixin Zhong et al.
CLINICAL LIPIDOLOGY (2015)
Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study
Reimar Wernich Thomsen et al.
DIABETES CARE (2015)
Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials
Nayyar Iqbal et al.
CARDIOVASCULAR DIABETOLOGY (2014)
DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study
Kazufumi Nakamura et al.
CARDIOVASCULAR DIABETOLOGY (2014)
Dipeptidyl Peptidase-4 Inhibitors and Cardiovascular Outcomes: Meta-Analysis of Randomized Clinical Trials with 55,141 Participants
Shiying Wu et al.
CARDIOVASCULAR THERAPEUTICS (2014)
Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial
Benjamin M. Scirica et al.
CIRCULATION (2014)
Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials
M. Monami et al.
DIABETES OBESITY & METABOLISM (2014)
Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors
Erin E. Mulvihill et al.
ENDOCRINE REVIEWS (2014)
Exenatide protects against hypoxia/reoxygenation-induced apoptosis by improving mitochondrial function in H9c2 cells
Guanglei Chang et al.
EXPERIMENTAL BIOLOGY AND MEDICINE (2014)
Hope and fear for new classes of type 2 diabetes drugs: is there preclinical evidence that incretin-based therapies alter pancreatic morphology?
Benjamin J. Lamont et al.
JOURNAL OF ENDOCRINOLOGY (2014)
Adenosine Deaminase Acts as a Natural Antagonist for Dipeptidyl Peptidase 4-Mediated Entry of the Middle East Respiratory Syndrome Coronavirus
V. Stalin Raj et al.
JOURNAL OF VIROLOGY (2014)
Mouse Dipeptidyl Peptidase 4 Is Not a Functional Receptor for Middle East Respiratory Syndrome Coronavirus Infection
Adam S. Cockrell et al.
JOURNAL OF VIROLOGY (2014)
Saxagliptin, Alogliptin, and Cardiovascular Outcomes
Eberhard Standl
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Dipeptidyl peptidase-4 inhibitors and heart failure: A meta-analysis of randomized clinical trials
M. Monami et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2014)
Do Dipeptidyl Peptidase-4 Inhibitors Increase the Risk of Heart Failure?
Deepak L. Bhatt et al.
JACC-HEART FAILURE (2014)
Sitagliptin Use in Patients With Diabetes and Heart Failure A Population-Based Retrospective Cohort Study
Daniala L. Weir et al.
JACC-HEART FAILURE (2014)
An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: Potential implications in cardiovascular disease
Jixin Zhong et al.
ATHEROSCLEROSIS (2013)
A Potential Role for Dendritic Cell/Macrophage-Expressing DPP4 in Obesity-Induced Visceral Inflammation
Jixin Zhong et al.
DIABETES (2013)
Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials
M. Monami et al.
DIABETES OBESITY & METABOLISM (2013)
Dipeptidylpeptidase Inhibition Is Associated with Improvement in Blood Pressure and Diastolic Function in Insulin-Resistant Male Zucker Obese Rats
Annayya R. Aroor et al.
ENDOCRINOLOGY (2013)
CD26/DPP4 Levels in Peripheral Blood and T Cells in Patients With Type 2 Diabetes Mellitus
Sang Ah Lee et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26
Guangwen Lu et al.
NATURE (2013)
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
William B. White et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Benjamin M. Scirica et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Dipeptidyl Peptidase-4 Inhibitors Attenuate Endothelial Function as Evaluated by Flow-Mediated Vasodilatation in Type 2 Diabetic Patients
Makoto Ayaori et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2013)
Glucagonlike Peptide 1-Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus A Population-Based Matched Case-Control Study
Sonal Singh et al.
JAMA INTERNAL MEDICINE (2013)
Meta-Analysis of Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Risk in Type 2 Diabetes Mellitus
Harshal R. Patil et al.
AMERICAN JOURNAL OF CARDIOLOGY (2012)
Dipeptidyl peptidase-4 inhibitor improves neovascularization by increasing circulating endothelial progenitor cells
Chun-Yao Huang et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Dipeptidyl Peptidase-4 Modulates Left Ventricular Dysfunction in Chronic Heart Failure via Angiogenesis-Dependent and -Independent Actions
Toshimasa Shigeta et al.
CIRCULATION (2012)
Cardiovascular effects of the DPP-4 inhibitors
Tessey Jose et al.
DIABETES & VASCULAR DISEASE RESEARCH (2012)
Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety
D. Nathanson et al.
DIABETOLOGIA (2012)
Cardiovascular Biology of the Incretin System
John R. Ussher et al.
ENDOCRINE REVIEWS (2012)
GLP1 and cancer: friend or foe?
Roman Vangoitsenhoven et al.
ENDOCRINE-RELATED CANCER (2012)
Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease
Philip A. Read et al.
HEART (2012)
Dipeptidyl Peptidase-4 Inhibition With Saxagliptin Enhanced Nitric Oxide Release and Reduced Blood Pressure and sICAM-1 Levels in Hypertensive Rats
R. Preston Mason et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2012)
Human Th17 Cells Express High Levels of Enzymatically Active Dipeptidylpeptidase IV (CD26)
Bertram Bengsch et al.
JOURNAL OF IMMUNOLOGY (2012)
A Dipeptidyl Peptidase-4 Inhibitor, Des-Fluoro-Sitagliptin, Improves Endothelial Function and Reduces Atherosclerotic Lesion Formation in Apolipoprotein E-Deficient Mice
Junichi Matsubara et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Effect of Heart Failure on Dipeptidyl Peptidase IV Activity in Plasma of Dogs
N. Gomez et al.
JOURNAL OF VETERINARY INTERNAL MEDICINE (2012)
Renal and Cardiac Effects of DPP-4 Inhibitors - from Preclinical Development to Clinical Research
Berthold Hocher et al.
KIDNEY & BLOOD PRESSURE RESEARCH (2012)
Increased hepatic expression of dipeptidyl peptidase-4 in non-alcoholic fatty liver disease and its association with insulin resistance and glucose metabolism
Masayuki Miyazaki et al.
MOLECULAR MEDICINE REPORTS (2012)
Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis
Hal E. Broxmeyer et al.
NATURE MEDICINE (2012)
Adaptive immunity in obesity and insulin resistance
Henrike Sell et al.
NATURE REVIEWS ENDOCRINOLOGY (2012)
Upregulation of CD26 expression in epithelial cells and stromal cells during wound-induced skin tumour formation
E. N. Arwert et al.
ONCOGENE (2012)
Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy
Anthony H. Barnett
ADVANCES IN THERAPY (2011)
Linagliptin approved for type 2 diabetes
Kate Traynor
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2011)
Altered dipeptidyl peptidase-4 activity during the progression of hyperinsulinemic obesity and islet atrophy in spontaneously late-stage type 2 diabetic rats
Yasushi Kirino et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2011)
Antiapoptotic effects of GLP-1 in murine HL-1 cardiomyocytes
Susana Ravassa et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2011)
Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury
Hiromasa Goto et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2011)
Pre-treatment with a DPP-4 Inhibitor is Infarct Sparing in Hearts from Obese, Pre-diabetic Rats
Barbara Huisamen et al.
CARDIOVASCULAR DRUGS AND THERAPY (2011)
Long-Term Dipeptidyl-Peptidase 4 Inhibition Reduces Atherosclerosis and Inflammation via Effects on Monocyte Recruitment and Chemotaxis
Zubair Shah et al.
CIRCULATION (2011)
Vildagliptin Improves Endothelium-Dependent Vasodilatation in Type 2 Diabetes
Pleun C. M. van Poppel et al.
DIABETES CARE (2011)
The Possible Protective Role of Glucagon-Like Peptide 1 on Endothelium During the Meal and Evidence for an Endothelial Resistance to Glucagon-Like Peptide 1 in Diabetes
Antonio Ceriello et al.
DIABETES CARE (2011)
Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice
M. Nagashima et al.
DIABETOLOGIA (2011)
Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1-Based Therapies
Michael Elashoff et al.
GASTROENTEROLOGY (2011)
Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways
Zubair Shah et al.
VASCULAR PHARMACOLOGY (2011)
Glucagon-Like Peptide-1 Increases Myocardial Glucose Uptake via p38α MAP Kinase-Mediated, Nitric Oxide-Dependent Mechanisms in Conscious Dogs With Dilated Cardiomyopathy
Siva Bhashyam et al.
CIRCULATION-HEART FAILURE (2010)
Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4
Masayuki Arakawa et al.
DIABETES (2010)
Genetic Deletion or Pharmacological Inhibition of Dipeptidyl Peptidase-4 Improves Cardiovascular Outcomes After Myocardial Infarction in Mice
Meghan Sauve et al.
DIABETES (2010)
Weight Loss, Glycemic Control, and Changes in Cardiovascular Biomarkers in Patients With Type 2 Diabetes Receiving Incretin Therapies or Insulin in a Large Cohort Database
Edward S. Horton et al.
DIABETES CARE (2010)
The Oral Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Increases Circulating Endothelial Progenitor Cells in Patients With Type 2 Diabetes Possible role of stromal-derived factor-1α
Gian Paolo Fadini et al.
DIABETES CARE (2010)
DURATION-1 Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks
John B. Buse et al.
DIABETES CARE (2010)
Inhibition of multifunctional dipeptidyl peptidase-IV: Is there a risk of oncological and immunological adverse effects?
Tomas Stulc et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2010)
The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice
J. Hsieh et al.
DIABETOLOGIA (2010)
被撤回的出版物: A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells (Retracted article. See vol. 55, pg. 533, 2012)
Y. Hattori et al.
DIABETOLOGIA (2010)
Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor
O. Erdogdu et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2010)
Dipeptydil peptidase-4 inhibitors in type 2 diabetes: A meta-analysis of randomized clinical trials
M. Monami et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2010)
Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes
Carolyn F. Deacon et al.
ADVANCES IN THERAPY (2009)
FDA approves saxagliptin for type 2 diabetes
Kate Traynor
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2009)
Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model
Kunio Hirata et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2009)
GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice
Mohammad Hossein Noyan-Ashraf et al.
DIABETES (2009)
DPP4 inhibitors for diabetes-What next?
Anne-Marie Lambeir et al.
BIOCHEMICAL PHARMACOLOGY (2008)
New drugs for the treatment of diabetes - Part II: Incretin-based therapy and beyond
Silvio E. Inzucchi et al.
CIRCULATION (2008)
Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways
Kiwon Ban et al.
CIRCULATION (2008)
Decreased dipeptidyl peptidase-IV activity and glucagon-like peptide-1(7-36)amide degradation in type 2 diabetic subjects
Aine M. McKillop et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2008)
Role of CD26/dipeptidyl peptidase IV in human T cell activation and function
Kei Ohnuma et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2008)
Efficacy and safety of incretin therapy in type 2 diabetes - Systematic review and meta-analysis
Renee E. Amori et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression
Silvia Deaglio et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2007)
Carrier frequency of a nonsense mutation in the adenosine deaminase (ADA) gene implies a high incidence of ADA-deficient severe combined immunodeficiency (SCID) in Somalia and a single, common haplotype indicates common ancestry
Juan J. Sanchez et al.
ANNALS OF HUMAN GENETICS (2007)
Biology of incretins: GLP-1 and GIP
Laurie L. Baggio et al.
GASTROENTEROLOGY (2007)
Caveolin-1 triggers T-cell activation via CD26 in association with CARMA1
Kei Ohnuma et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting
George G. Sokos et al.
AMERICAN JOURNAL OF CARDIOLOGY (2007)
Inflammation and metabolic disorders
Goekhan S. Hotamisligil
NATURE (2006)
Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure
George G. Sokos et al.
JOURNAL OF CARDIAC FAILURE (2006)
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Daniel J. Drucker et al.
LANCET (2006)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus
I. Raz et al.
DIABETOLOGIA (2006)
Ex vivo gene therapy with lentiviral vectors rescues adenosine deaminase (ADA)-deficient mice and corrects their immune and metabolic defects
Alessandra Mortellaro et al.
BLOOD (2006)
Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1
Brian D. Green et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2006)
Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake
Jakob Ryskjaer et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2006)
Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes
L. Blonde et al.
DIABETES OBESITY & METABOLISM (2006)
Sitagliptin: A dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
Shannon A. Miller et al.
ANNALS OF PHARMACOTHERAPY (2006)
Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts
Tingcun Zhao et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Transcription factor Fox01 mediates glucagon-like peptide-1 effects on pancreatic β-cell mass
J Buteau et al.
DIABETES (2006)
Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans
JJ Meier et al.
DIABETOLOGIA (2006)
CD26 mediates dissociation of Tollip and IRAK-1 from caveolin-1 and induces upregulation of CD86 on antigen-presenting cells
K Ohnuma et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus
L Pala et al.
DIABETOLOGIA (2005)
GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats
XF Qin et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2005)
Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes
JR Lindsay et al.
DIABETIC MEDICINE (2005)
Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders
MD Gorrell
CLINICAL SCIENCE (2005)
Sulphostin, a novel inhibitor of dipeptidyl peptidases IV (DPPIV) that stimulates hematopoiesis in mice
M Abe et al.
JOURNAL OF ANTIBIOTICS (2005)
Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion
LA Nikolaidis et al.
CIRCULATION (2004)
Glucagon-like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion
R Lugari et al.
HORMONE AND METABOLIC RESEARCH (2004)
CD26 up-regulates expression of CD86 on antigen-presenting cells by means of caveolin-1
K Ohnuma et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy
LA Nikolaidis et al.
CIRCULATION (2004)
Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease
T Nyström et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2004)
Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments
JM Lenhard et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance
SL Conarello et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Similar increased serum dipeptidyl peptidase IV activity in chronic hepatitis C and other viral infections
T Andrieu et al.
JOURNAL OF CLINICAL VIROLOGY (2003)
The crystal structure of dipeptidyl peptidase IV(CD26) reveals its functional regulation and enzymatic mechanism
M Engel et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5′-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway
HX Hui et al.
ENDOCRINOLOGY (2003)
International union of pharmacology.: XXXV.: The glucagon receptor family
KE Mayo et al.
PHARMACOLOGICAL REVIEWS (2003)
Soluble CD26/dipeptidyl peptidase IV induces T cell proliferation through CD86 up-regulation on APCs
K Ohnuma et al.
JOURNAL OF IMMUNOLOGY (2001)
Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes
MGV Petroff et al.
CIRCULATION RESEARCH (2001)
The binding site of human adenosine deaminase for CD26/dipeptidyl peptidase IV: The Arg142Gln mutation impairs binding to CD26 but does not cause immune deficiency
E Richard et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Mechanisms of CD26/dipeptidyl peptidase IV cytokine-dependent regulation on human activated lymphocytes
FJ Salgado et al.
CYTOKINE (2000)
Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26
D Marguet et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Role of hepatocyte nuclear factor 1α and 1β in the transcriptional regulation of human dipeptidyl peptidase IV during differentiation of Caco-2 cells
RH Erickson et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2000)
Regulation of CD26/DPPIV gene expression by interferons and retinoic acid in tumor B cells
B Bauvois et al.
ONCOGENE (2000)
分享论文
